Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Calcium antagonists decrease adrenal and vascular responsiveness to angiotensin II in normal man

J A Millar, K McLean, J L Reid

    Clinical Science (London, England : 1979)
    |December 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Estimation of clinical and economic effects of prophylaxis against venous thromboembolism in medical patients, including the effect of targeting patients at high-risk.

    Internal medicine journal·2016
    Same author

    A comparison and an investigation of a potential synergistic effect of labetalol and bethanidine in patients with mild hypertension.

    British journal of clinical pharmacology·2015
    Same author

    Cerebral abscess following adenotonsillectomy: a rare complication.

    Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale·2011
    Same author

    Selection of medical patients for prophylaxis of venous thromboembolism based on analysis of the benefit-hazard ratio.

    Internal medicine journal·2009
    Same author

    Multicentre drug trials, ethics approval and death of patients.

    Internal medicine journal·2008
    Same author

    Is the Australian HREC system unsustainable?

    Monash bioethics review·2005
    Same journal

    Edaravone Dexborneol regulates the endothelial PPARγ-PON1 axis to inhibit high-cholesterol-induced atherosclerosis.

    Clinical science (London, England : 1979)·2026
    Same journal

    HDAC9 promotes atherosclerosis by suppressing CYP7A1 and impairing hepatic cholesterol excretion.

    Clinical science (London, England : 1979)·2026
    Same journal

    Clusterin ameliorates LPS-induced ARDS by inhibiting the Wnt/β-catenin pathway.

    Clinical science (London, England : 1979)·2026
    Same journal

    Human cytomegalovirus at the maternal-fetal interface: an overview of pathogenesis, defence, and interventions.

    Clinical science (London, England : 1979)·2026
    Same journal

    Cardiometabolic regulation by adipocyte-derived leptin and the brain melanocortin system.

    Clinical science (London, England : 1979)·2026
    Same journal

    Impact of impaired branched-chain amino acid metabolism on kidney disease.

    Clinical science (London, England : 1979)·2026
    See all related articles

    Nifedipine, a calcium channel blocker, reduces the blood pressure and aldosterone response to angiotensin II in humans. This suggests calcium

    Area of Science:

    • Cardiovascular Pharmacology
    • Endocrinology

    Background:

    • Angiotensin II is a potent vasoconstrictor and stimulates aldosterone release.
    • Calcium ions play a crucial role in cellular signaling pathways, including those regulating hormone secretion and vascular tone.

    Purpose of the Study:

    • To investigate the effect of the calcium antagonist nifedipine on the pressor and aldosterone responses to angiotensin II in normal subjects.
    • To elucidate the role of transmembrane calcium movement in the aldosterone response to angiotensin II.

    Main Methods:

    • Six normal subjects received infusions of angiotensin II at varying doses (5, 10, 20 ng/min/kg) on two separate occasions.
    • Nifedipine (20 mg orally) was administered 30 minutes prior to the second set of angiotensin II infusions.
    • Blood pressure, pulse rate, and plasma levels of aldosterone, potassium, and cortisol were measured.

    Related Experiment Videos

    Main Results:

    • Nifedipine administration resulted in a significant decrease in the pressor response to angiotensin II (P < 0.05).
    • While basal aldosterone levels remained unchanged, nifedipine significantly attenuated the aldosterone response to angiotensin II (P < 0.05).
    • Nifedipine did not affect plasma potassium or cortisol levels.

    Conclusions:

    • Transmembrane calcium movement is implicated in mediating the aldosterone response to angiotensin II in humans.
    • Calcium antagonists like nifedipine may lower blood pressure through reduced adrenal responsiveness to angiotensin II, in addition to peripheral vasodilation.